Figure 2From: EGFR gene copy number as a predictive biomarker for the treatment of metastatic colorectal cancer with anti-EGFR monoclonal antibodies: a meta-analysisDifference in objective response rate between GCN + and GCN- patients. For GCN + group, the total events and patients were 125 and 301, respectively. For GCN- group, the total events and patients were 106 and 590, respectively. Heterogeneity test: P <0.00001, I2 = 78%.Back to article page